U.S. Markets closed
  • S&P 500

    4,354.19
    -3.54 (-0.08%)
     
  • Dow 30

    33,919.84
    -50.63 (-0.15%)
     
  • Nasdaq

    14,746.40
    +32.49 (+0.22%)
     
  • Russell 2000

    2,186.18
    +3.98 (+0.18%)
     
  • Crude Oil

    70.51
    +0.22 (+0.31%)
     
  • Gold

    1,775.00
    +11.20 (+0.63%)
     
  • Silver

    22.53
    +0.37 (+1.68%)
     
  • EUR/USD

    1.1729
    +0.0001 (+0.0117%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3664
    +0.0005 (+0.0355%)
     
  • USD/JPY

    109.2150
    -0.2050 (-0.1874%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,016.33
    -47.52 (-4.47%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Caladrius Biosciences Inc (NASDAQ: CLBS) has received .4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

  • The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.

  • Cassava Sciences Inc (NASDAQ: SAVA) has been awarded a new .7 million research grant award from the National Institutes of Health.

  • The grant will be used to fund its upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer's disease.

  • Price Action: CLBS shares are trading 0.68% lower at $1.45, and SAVA shares are down 2.73% at $38.16 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.